Shyh-Han Tan, PhD
My work focuses on understanding why some prostate cancers become aggressive and how we can use molecular information to predict which patients are at highest risk. I combine genomic, proteomic, and clinical data to uncover the biological pathways that drive tumor progression and to translate these insights into practical biomarkers that can guide care. I am particularly interested in how inherited factors and the tumor microenvironment influence cancer behavior, and in developing tools that improve early detection and risk assessment. I also enjoy working collaboratively across disciplines and mentoring trainees as we build approaches that connect molecular insights to meaningful clinical improvements for patients.
| Guan K, Guan A, Ahmed AE, Waters AJ, Tan SH, Chen D. Using machine learning to create prognostic systems for primary prostate cancer. Diagnostics (Basel). 2025;15(19):2462. Epub 20250926. doi: 10.3390/diagnostics15192462. PubMed PMID: 41095681; PMCID: PMC12523577. |
| Patkar S, Harmon S, Sesterhenn I, Lis R, Merino M, Young D, Brown GT, Greenfield KM, McGeeney JD, Elsamanoudi S, Tan SH, Schafer C, Jiang J, Petrovics G, Dobi A, Rentas FJ, Pinto PA, Chesnut GT, Choyke P, Turkbey B, Moncur JT. A selective cutmix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer. J Pathol Inform. 2024;15:100381. Epub 20240507. doi: 10.1016/j.jpi.2024.100381. PubMed PMID: 38953042; PMCID: PMC11215954. |
| Schafer CC, Jiang J, Elsamanoudi S, Nousome D, Young DY, Song Y, Sesterhenn IA, Chesnut GT, Tan SH. Immunologic assessment of tumors from a race-matched military cohort identifies mast cell depletion as a marker of prostate cancer progression. Cancer Res Commun. 2023;3(8):1423-34. Epub 20230801. doi: 10.1158/2767-9764.CRC-22-0463. PubMed PMID: 37534375; PMCID: PMC10392708. |
| Petrovics G, Li H, Stumpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A. A novel genomic alteration of lsamp associates with aggressive prostate cancer in african american men. EBioMedicine. 2015;2(12):1957-64. Epub 2016/02/05. doi: 10.1016/j.ebiom.2015.10.028. PubMed PMID: 26844274; PMCID: 4703707. |
| Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH. Erg oncoprotein inhibits anxa2 expression and function in prostate cancer. Mol Cancer Res. 2015;13(2):368-79. Epub 2014/10/26. doi: 10.1158/1541-7786.MCR-14-0275-T. PubMed PMID: 25344575; PMCID: 4336823. |
| Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA. Erg oncoprotein expression in prostate cancer: Clonal progression of erg-positive tumor cells and potential for erg-based stratification. Prostate Cancer Prostatic Dis. 2010;13(3):228-37. Epub 2010/06/30. doi: pcan201023 [pii] 10.1038/pcan.2010.23. PubMed PMID: 20585344. |
| Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. Transcription factor stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res. 2008;68(1):236-48. Epub 2008/01/04. doi: 68/1/236 [pii] 10.1158/0008-5472.CAN-07-2972. PubMed PMID: 18172316. |
Area of Research
Institution Affiliations
HJF Adjunct Investigator in support of Genitourinary Malignancies Branch, National Cancer Institute
Associate Professor, Surgery, Uniformed Services University of the Health Sciences